ReviewDiscover nano2025
Advancing malaria treatment with magnetic and mesoporous silica nanoparticles loaded with sulfadoxine-pyrimethamine: a review.
Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanoparticle based drug delivery systems improve antimalarial efficacy and vaccine performance in African research and clinical settings.Discover nano · 2026Review
- [Performance of PHMB-surface mesoporous silica composite material and its effect on infected full-thickness skin defect wounds in rats].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Article
- Ligand decorated nanostructure carrier systems for targeted delivery of antimalarials.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria remains a pressing global health concern, particularly in regions with rising cases of drug-resistant Plasmodium strains. Sulphadoxine-pyrimethamine (SP), a widely used antimalarial drug combination, faces challenges such as reduced bioavailability, systemic toxicity, and diminished efficacy due to resistance. In response, nanotechnology offers innovative strategies to improve SP delivery and therapeutic outcomes. This review focuses on the potential of magnetic and mesoporous silica nanoparticles as advanced drug delivery platforms for SPs. Magnetic and mesoporous silica nanoparticles combine a magnetic core, enabling targeted delivery through external magnetic fields, with a mesoporous silica shell that allows high drug loading and controlled release. This review explores recent advancements in magnetic and mesoporous silica nanoparticles synthesis, surface functionalization, and drug encapsulation techniques, highlighting their ability to increase SP bioavailability, ensure sustained drug release, and minimize off-target effects. In vitro and in vivo studies have demonstrated the improved pharmacokinetics, reduced toxicity, and enhanced antimalarial efficacy of SP-loaded magnetic and mesoporous silica nanoparticles, particularly against resistant Plasmodium strains. Additionally, the versatility of magnetic and mesoporous silica nanoparticles paves the way for the codelivery of synergistic drugs and the development of theranostic systems. While magnetic and mesoporous silica nanoparticles show immense promise, challenges such as scalability, biocompatibility, and regulatory hurdles must be addressed to facilitate clinical translation. By bridging nanotechnology with malaria treatment, this approach has the potential to revolutionize antimalarial therapy, providing a scalable and effective solution for resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.